Search clinical trials for: Nivolumab 240mg

Total 2749 results

CrystalGenomics, Inc.

Completed

Multiple Ascending Doses Study of CG400549

Healthy

Netherlands
RemeGen Co., Ltd.

Completed

A Phase I Study of TACI-antibody Fusion Protein Injection (RC18) in Healthy Adult Chinese Subjects

Healthy

China
Universitätsklinikum Hamburg-Eppendorf
Charite University, Berlin, Germany; University Hospital, Essen; Westpfalz-Clinical...

Active, not recruiting

Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy (IMSTAR-HN)

Head and Neck Cancer

Germany
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

Lung Cancer

Italy, United States, France, Russian Federation, Spain, Argentina, Belgium, Brazil, Canada, Chile, Czechia, Germany, Greece, Hungary, Mexico, Netherlands, Poland, Romania, Switzerland, Turkey, United Kingdom
University of California, San Francisco
Bristol-Myers Squibb; National Cancer Institute (NCI)

Completed

Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma

HIV/AIDS | Kaposi Sarcoma | Immunosuppression

United States
Obafemi Awolowo University Teaching Hospital
Open Philanthropy

Recruiting

ATORvastatin in Pulmonary TUBerculosis (ATORTUB)

Tuberculosis | Pulmonary Tuberculosis | Koch's Disease

Nigeria
Parker Institute for Cancer Immunotherapy
Bristol-Myers Squibb; Cancer Research Institute, New York City

Completed

Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer

Advanced Metastatic Cancer | Advanced Prostate Cancer

United States
Ascletis Pharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

Chronic Hepatitis c

China
HK inno.N Corporation

Completed

Food-Effect on PK and PD of Single Oral Dose of CJ-12420 in Healthy Male Subjects

Healthy

Korea, Republic of
IRCCS San Raffaele
Bristol-Myers Squibb

Recruiting

An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo) (NURE-Combo)

Muscle-Invasive Bladder Carcinoma

Italy
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Study on Safety, Absorption and Metabolism of SYHA1402 Tablets in Healthy People

Diabetic Neuropathy Peripheral

China
National Health Research Institutes, Taiwan
National Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaborators

Recruiting

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC)

Taiwan
Pfizer

Completed

STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT

Healthy Volunteers | Hepatic Impairment

United States
Impact Therapeutics, Inc.

Not yet recruiting

An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition

Solid Tumor
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

Bladder Cancer | Urothelial Carcinoma

United States
Boehringer Ingelheim

Completed

LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

Carcinoma, Non-Small-Cell Lung

Japan
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) (NIVO-ALCL)

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma

France, Denmark, Netherlands
Daewoong Pharmaceutical Co. LTD.

Unknown

Clinical Trail to Evaluate the Efficacy and Safety of DWJ1451

Hypertension, Dyslipidemia

Korea, Republic of
Bio Genuine (Shanghai) Biotech Co., Ltd.

Recruiting

Efficacy and Safety of BG2109 in Chinese Subjects With Endometriosis

Endometriosis | Moderate to Severe Endometriosis-associated Pain

China
Amgen

Recruiting

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Melanoma

Spain, Italy, South Africa, Japan, Serbia, Bosnia and Herzegovina, United States, Argentina, Chile, Georgia, Malaysia, Korea, Republic of, France, Germany, Croatia, Thailand, Brazil, Taiwan, Romania, Mexico, Netherlands
University of Chicago

Recruiting

Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers

Metastatic Cancer

United States
Shanghai Chest Hospital

Not yet recruiting

Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH) (neoR-TORCH)

Stage II-III Non-small Cell Lung Cancer
Robert Ritch, MD, LLC.

Unknown

Measurement of the Effect of Gingko Biloba Extract on Ocular and Nailfold Blood-flow in NTG

Normal Tension Glaucoma

United States
Onconic Therapeutics Inc.

Not yet recruiting

Clinical Trial to Evaluate Food-Effects on Pharmacokinetics and Pharmacodynamics of Oral Single Dose of JP-1366 Tablet in Healthy Volunteers

Healthy

Korea, Republic of
Impact Therapeutics, Inc.

Not yet recruiting

An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting Condition

Solid Tumor
Haisco Pharmaceutical Group Co., Ltd.

Active, not recruiting

To Evaluate the Long-term Safety and Efficacy of HSK16149 in Chinese Patients With Peripheral Neuralgia

Peripheral Neuropathic Pain

China
Ontario Clinical Oncology Group (OCOG)
Bristol-Myers Squibb

Active, not recruiting

SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (CYTOSHRINK)

Metastatic Renal Cell Carcinoma

Canada, Australia
University of Pittsburgh
Bristol-Myers Squibb

Withdrawn

Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone

Melanoma

United States
Andrew Carr

Completed

Safety, Tolerability,and Adherence to Co-formulated Tenofovir-emtricitabine-rilpivirine Used as HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men. (EPEP)

HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men

Australia
Addpharma Inc.

Completed

Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072

Hypertension | Hyperlipidemias

Korea, Republic of
Reckitt Benckiser Healthcare (UK) Limited
Premier Research Group plc

Completed

Ibuprofen Liquid Capsules 2 x 200 mg Efficacy and PK/PD Study in Surgical Removal of Impacted Third Molars

Stomatognathic Diseases | Tooth Diseases | Tooth, Impacted

United States
GERCOR - Multidisciplinary Oncology Cooperative...
Bristol-Myers Squibb

Recruiting

Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. (NIPISAFE)

Colorectal Cancer Metastatic | MSI-H Colorectal Cancer

France
Dan Zandberg
Bristol-Myers Squibb

Active, not recruiting

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Squamous Cell Carcinoma of the Head and Neck

United States
Sarfez Pharmaceuticals, Inc.
Sarfez Pharmaceuticals, Inc.

Recruiting

Immediate Release Versus Extended Release Torsemide After Salty Meal

Heart Failure

United States
Victoria Rollason

Active, not recruiting

PROGRESSive Withdrawal Esomeprazole and Acid-related Symptoms (PROGRESS)

Stomach Diseases

Switzerland
Global Alliance for TB Drug Development

Completed

Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects (CL-009) (CL-009)

Tuberculosis

United States
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma (NADINA)

Malignant Melanoma Stage III

United States, Netherlands, Australia
Bristol-Myers Squibb

Completed

A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney (CheckMate 914)

Carcinoma, Renal Cell

United States, Italy, Brazil, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, France, Germany, Japan, Mexico, Netherlands, Poland, Romania, Russian Federation, Singapore, Spain, Switzerland, Turkey, United...
TiumBio Co., Ltd.

Recruiting

TUC3PII-01_TU2670 Phase IIa Clinical Study

Endometriosis

Czechia, Italy, Russian Federation, Poland, Ukraine
Case Comprehensive Cancer Center

Withdrawn

Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer

Metastatic Colorectal Cancer
IlDong Pharmaceutical Co Ltd

Completed

Pharmacokinetic Study of Belviq in Adult Korean Volunteers

Healthy

Korea, Republic of
Harbour BioMed (Guangzhou) Co. Ltd.

Not yet recruiting

Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

Myasthenia Gravis

China
Medical College of Wisconsin

Terminated

Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant

Lymphoma | Myelodysplastic Syndromes | Acute Leukemia | Chronic Leukemia

United States
Fondazione Ricerca Traslazionale
Clinical Research Technology S.r.l.

Unknown

An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC) (SQUINT)

Squamous-Cell Lung Cancer

Italy
Hoffmann-La Roche

Completed

A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.

Psoriasis

United States
NYU Langone Health

Completed

Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)

Breast Cancer

United States
Samjin Pharmaceutical Co., Ltd.

Completed

Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers

Healthy
Italian Network for Tumor Biotherapy Foundation
Bristol-Myers Squibb; Astex Pharmaceuticals, Inc.

Not yet recruiting

A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 (NIBIT-ML1)

Melanoma | Non Small Cell Lung Cancer

Italy
Universitätsklinikum Köln
ZKS Köln

Withdrawn

Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients (CERAD-IMMUNE)

Cervical Cancer ≥ FIGO IIB and or Lymph Node Metastases
Kyowa Kirin, Inc.
Bristol-Myers Squibb

Completed

Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors

Carcinoma | HCC | Cancer | Hepatocellular Carcinoma | Solid Tumor

United States

Search clinical trials for: Nivolumab 240mg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations